Arginine vasopressin (AVP), also called antidiuretic hormone (ADH), is a 9-amino acid cyclic neuropeptide synthesized in hypothalamic magnocellular neurons and released from the posterior pituitary. AVP serves dual master roles: regulating water homeostasis via renal V2 receptors and modulating vascular tone via V1a receptors as a potent vasopressor.
Arginine vasopressin (AVP), also called antidiuretic hormone (ADH), is a 9-amino acid cyclic neuropeptide synthesized in hypothalamic magnocellular neurons and released from the posterior pituitary. AVP serves dual master roles: regulating water homeostasis via renal V2 receptors and modulating vascular tone via V1a receptors as a potent vasopressor. Beyond these classical functions, AVP acts as a neuromodulator in the brain through V1a and V1b receptors, influencing social behavior, trust, pair bonding, stress responses, and memory. AVP's behavioral roles mirror those of closely related oxytocin, and the interaction between these two systems shapes much of mammalian social neuroscience.
Peptide calculator
Storage Stability
Lyophilized
6-12 months (2-8°C)
Reconstituted
~30 days (2-8°C)
Room temp
Avoid
Mechanism of Action
V1a, V1b, and V2 Receptor Subtypes
AVP signals through three main GPCRs. V1a (Gq-coupled) in vascular smooth muscle mediates potent vasoconstriction by increasing intracellular calcium. V1b (Gq-coupled) in the pituitary anterior lobe synergizes with CRH to stimulate ACTH release during stress. V2 (Gs-coupled) in the renal collecting duct activates aquaporin-2 (AQP2) insertion into apical membranes, dramatically increasing water reabsorption and concentrating urine.
Social Behavior and Neuromodulation
V1a receptors distributed across the limbic system, olfactory bulb, lateral septum, and basal ganglia mediate AVP's behavioral effects. V1a signaling modulates territorial behavior, aggression, paternal care, and social memory. The density of V1a receptors in the ventral pallidum predicts pair-bonding fidelity in prairie voles, establishing AVP as a molecular substrate of social attachment. Intranasal AVP in humans increases attention to facial emotions and modulates trust.
Research Summary
Vasopressor and Shock Treatment
Human
IV vasopressin is a first-line vasopressor in septic shock and other distributive shock states, approved as Vasostrict. At doses of 0.03-0.04 U/min, AVP restores vasomotor tone in catecholamine-resistant shock through V1a-mediated vasoconstriction. It is often combined with norepinephrine to allow norepinephrine dose reduction.
Diabetes Insipidus
Human
Central (hypothalamic) diabetes insipidus results from AVP deficiency and is treated with desmopressin (DDAVP), a synthetic V2-selective AVP analog. Desmopressin is FDA-approved in multiple forms including intranasal, oral, and injectable, with decades of clinical experience in both children and adults.
Social Behavior and Autism Research
Human
Intranasal AVP trials in autism spectrum disorder and social anxiety disorder showed mixed but encouraging results in improving social recognition, reducing social anxiety, and enhancing emotion recognition. These trials stem from robust animal and human neuroscience linking AVP to social cognition circuits.
Therapeutic uses (vasopressor, DI) are well established. Behavioral research uses intranasal delivery for CNS targeting without systemic vasopressor effects.
Structurally related; both modulate social behavior and bonding but with distinct receptor profiles and often opposing behavioral effects
Synergistic
CRH
AVP synergizes with CRH to stimulate pituitary ACTH release during stress through V1b receptors
Opposing
ANP
ANP promotes natriuresis and water excretion; AVP promotes water reabsorption, opposing renal water regulators
Safety Profile
IV vasopressin at vasopressor doses causes digital, mesenteric, and coronary vasoconstriction, monitoring for ischemia is required. Hyponatremia from excess water retention is a dose-dependent risk. Intranasal AVP at behavioral research doses (20-40 IU) is generally well tolerated with minimal systemic effects. Water retention headache and mild hypertension are the most common effects at research intranasal doses.
References
[1]Du Vigneaud V, et al. The synthesis of an octapeptide amide with the hormonal activity of oxytocin. J Am Chem Soc. 1953;75(19):4879-4880.
[2]Landgraf R, Neumann ID. Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication. Front Neuroendocrinol. 2004.
[3]Russell JA, et al. Vasopressin and norepinephrine in septic shock. N Engl J Med. 2008;358(9):877-887.
Social Behavior and Neuromodulation
V1a receptors distributed across the limbic system, olfactory bulb, lateral septum, and basal ganglia mediate AVP's behavioral effects. V1a signaling modulates territorial behavior, aggression, paternal care, and social memory. The density of V1a receptors in the ventral pallidum predicts pair-bonding fidelity in prairie voles, establishing AVP as a molecular substrate of social attachment. Intranasal AVP in humans increases attention to facial emotions and modulates trust.